Position in BCYC
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$296,523
+$51,528 QoQ
Shares Held
63,906
+121.5% QoQ
Ownership
0.091%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCYC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026EntryPoint Capital, LLC holds $19,701,077 across 57 Biotechnology names. BCYC ranks #32 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TBPH |
Theravance Biopharma, Inc.
|
49,739 | $807,263 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
3,922 | $783,027 | |
| 3 | ADMA |
Adma Biologics, Inc.
|
83,961 | $756,488 | |
| 4 | VCEL |
Vericel Corp
|
22,674 | $729,422 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
24,264 | $679,634 | |
| 6 | UPB |
Upstream Bio, Inc.
|
73,568 | $662,112 | |
| 7 | INCY |
Incyte Corp
|
6,483 | $610,179 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
26,119 | $547,193 |
All Filings in BCYC
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $296,523 | 63,906 | Shares | Sole | 2026-05-14 | |
| 2025-03-31 | $244,995 | 28,857 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $614,222 | 43,873 | Shares | Sole | 2025-02-11 | |
| 2023-12-31 | $334,389 | 18,495 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||